Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype
Chondrosarcoma (ChS) is a primary malignant bone tumor. Due to its heterogeneity in clinical outcomes and resistance to chemo- and radiotherapies, there is a need to develop new potential therapies and molecular targets of drugs. Many genes and pathways are involved in in ChS progression. The most f...
Main Authors: | Agnieszka Zając, Sylwia K. Król, Piotr Rutkowski, Anna M. Czarnecka |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/6/1317 |
Similar Items
-
MicroRNAs as Prognostic Biomarkers and Therapeutic Targets in Chondrosarcoma
by: Palina Skipar, et al.
Published: (2024-03-01) -
Mesenchymal Chondrosarcoma from Diagnosis to Clinical Trials
by: Monika Dudzisz-Śledź, et al.
Published: (2023-09-01) -
Laryngeal Chondrosarcoma of the Thyroid Cartilage
by: Selma ERDOĞAN DÜZCÜ, et al.
Published: (2021-05-01) -
Chondrosarcoma of the mandible: A case report
by: J Yaghini, et al.
Published: (2010-01-01) -
Epigenetic Abnormalities in Chondrosarcoma
by: Michał Bereza, et al.
Published: (2023-02-01)